ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.

W. W. Hope, E. Castagnola, A. H. Groll, E. Roilides, M. Akova, M. C. Arendrup, S. Arikan-Akdagli, M. Bassetti, J. Bille, O. A. Cornely, M. Cuenca-Estrella, J. P. Donnelly, J. Garbino, R. Herbrecht, H. E. Jensen, B. J. Kullberg, C. Lass-Flörl, O. Lortholary, W. Meersseman, G. PetrikkosM. D. Richardson, P. E. Verweij, C. Viscoli, A. J. Ullmann

Research output: Contribution to journalArticle

Abstract

Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality. These guidelines provide recommendations for the prevention and treatment of IC in neonates and children. Appropriate agents for the prevention of IC in neonates at high risk include fluconazole (A-I), nystatin (B-II) or lactoferrin±Lactobacillus (B-II). The treatment of IC in neonates is complicated by the high likelihood of disseminated disease, including the possibility of infection within the central nervous system. Amphotericin B deoxycholate (B-II), liposomal amphotericin B (B-II), amphotericin B lipid complex (ABLC) (C-II), fluconazole (B-II), micafungin (B-II) and caspofungin (C-II) can all be potentially used. Recommendations for the prevention of IC in children are largely extrapolated from studies performed in adults with concomitant pharmacokinetic data and models in children. For allogeneic HSCT recipients, fluconazole (A-I), voriconazole (A-I), micafungin (A-I), itraconazole (B-II) and posaconazole (B-II) can all be used. Similar recommendations are made for the prevention of IC in children in other risk groups. With several exceptions, recommendations for the treatment of IC in children are extrapolated from adult studies, with concomitant pharmacokinetic studies. Amphotericin B deoxycholate (C-I), liposomal amphotericin B (A-I), ABLC (B-II), micafungin (A-I), caspofungin (A-I), anidulafungin (B-II), fluconazole (B-I) and voriconazole (B-I) can all be used.

Original languageEnglish
Pages (from-to)38-52
Number of pages15
JournalClinical Microbiology and Infection
Volume18
Issue numberSUPPL.7
DOIs
Publication statusPublished - Dec 2012

Keywords

  • Antifungal agents
  • Candida disease
  • Children
  • Europe
  • Neonates

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Medicine(all)

Fingerprint Dive into the research topics of 'ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.'. Together they form a unique fingerprint.

  • Cite this

    Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., Cuenca-Estrella, M., Donnelly, J. P., Garbino, J., Herbrecht, R., Jensen, H. E., Kullberg, B. J., Lass-Flörl, C., Lortholary, O., Meersseman, W., ... Ullmann, A. J. (2012). ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp. Clinical Microbiology and Infection, 18(SUPPL.7), 38-52. https://doi.org/10.1111/1469-0691.12040